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Abstract
Background: Clinical trials are the hallmark of evidence-based medicine, but recruitment is often challenging, especially
in stroke trials investigating patients not being able to give informed consent. In some nations, ethics committees will
not approve of inclusion in a clinical study via consent of a legal representative. The ethical dilemma of including
or excluding those patients has not been properly addressed, as there is little data on the effect of stroke characteristics
on the ability to give informed consent.
Methods: To examine differences between patients able and unable to consent at inclusion to an acute stroke
trial, we conducted a post-hoc analysis of monitoring records from a multicentric interventional trial. These records
listed patients who gave informed consent by themselves and those who needed a legal representative to do so. This
exemplary STRAWINSKI trial aimed at improving stroke outcome by biomarker-guided antibiotic treatment of stroke
associated pneumonia and included patients within 40 h after stroke onset, suffering from MCA infarctions with
an NIHSS score > 9 at admission. Standard descriptive and associative statistics were calculated to compare baseline
characteristics and outcome measures between patients who were able to consent and those who were not.
Results: We identified the person giving consent in 228 out of 229 subjects. Patients with inability to consent were
older (p < 0.01), suffered from more left-hemispheric (p < 0.01) and more severe strokes (NIHSS, p < 0.01), were more
likely to die during hospitalisation (p < 0.01) or have unfavourable outcome at discharge (mRS, p < 0.01), to develop
fever (p < 0.01) and tended to be more susceptible to infections (p = 0.06) during the acute course of the disorder.
Conclusions: Demographics, stroke characteristics and outcomes significantly affect stroke patients in their ability to
consent. Where selection criteria and primary outcome measures of a trial are significantly affected by ability to consent,
excluding patients unable to consent might be unethical.
Trial registration: URL http://www.clinicaltrials.gov. Unique identifier: NCT01264549.
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Background
Clinical trials often suffer from low recruitment with
subsequently prolonged duration of the trials [1]. Previ-
ous work has identified special obstacles stroke research
has to face. Not only is the time window of intervention
limited by pathophysiological circumstances, but also,
ability of patients to provide informed consent is fre-
quently impeded due to disabilities caused by the stroke
itself [2–4]. Regulatory approaches to clinical research
with patients unable to give informed consent them-
selves differ substantially between countries [5, 6]. In the
USA, regulations differ strongly between federal states,
with some of them not having formal criteria of what
constitutes a sufficiently authorized legal representative,
leaving interpretation to investigators and ethics commit-
tees. In some countries – like Germany – the authorization
to obtain informed consent by a legal representative might
even be declined totally in one federal state, but granted in
another. Some legislators - for instance in the USA and
United Kingdom – now provide a framework for ex-
ceptions or “waivers” of consent to address this issue,
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frequently with a list of criteria the target population and
the trial need to meet [7, 8]. Usually these include the
condition studied to be acutely life-threatening, with unsat-
isfactory treatment options, frequently or regularly render-
ing the patients unable to consent. While the incapacity to
consent is widely recognized as a major obstacle as well as
an ethical dilemma of clinical trials in critical care, neur-
ology and cognitive decline [9, 10], quantitative data char-
acterising consenting and influencing parameters in these
settings are very limited [11, 12]. The third international
stroke trial (IST-3) reported different stroke severity and
outcome based on the method of consent, but stands alone
in the field of stroke research to do so [13].
This issue is of major significance, since some treat-
ments can only be studied in patients severely affected
by stroke. Patients who are only mildly affected have a
higher probability to recover without any intervention
[14]. The ability to consent is strongly linked to age, the
severity and localisation of stroke [3, 15]. Furthermore,
stroke-related complications such as post-stroke infec-
tions mainly occur in severely affected patients. Dyspha-
gia and Central Nervous System-injury induced immune
depression syndrome are the main risk factors for
stroke-associated pneumonia (SAP) [16–18]. The fre-
quency of SAP strongly correlates with the National
Institute of Health Stroke Scale (NIHSS) score at admis-
sion [19].
To investigate possible selection bias introduced into
clinical trials based on ability to give informed consent we
analysed data from the “STRoke Adverse outcome is as-
sociated WIth NoSocomial Infections” (STRAWINSKI)
trial. The trial was designed to analyse treatment-guidance
for antibiotics by the use of ultrasensitive Procalcitonin
(PCTus) as a marker for bacterial infections. For STRA-
WINSKI regulatory authorities granted permission to
include patients by a legal representative (usually a next-
of-kin) as well as by personal informed consent. Based on
an explorative analysis we aimed at identifying differences
between both groups in order to estimate the bias intro-
duced when only including patients able to give informed
consent personally.
Methods
The dataset from the STRAWINSKI trial
The NeuroCure Clinical Research Center Berlin initiated
a multicentric, randomized, open-label treatment guid-
ance trial on application of antibiotics with PCTus and
blinded outcome assessment called “STRoke Adverse
outcome is associated With NoSocomial Infections”
(STRAWINSKI). Primary outcome of this trial was the
proportion of patients with an mRS of 0–4 at day 90
after stroke [20]. Further information can be found in
the published protocol and at clinicaltrials.gov
(NCT01264549) [21]. STRAWINSKI was reviewed and
approved by the appropriate ethics committees (Charité
- Universitätsmedizin Berlin [reference EA1/267/10],
State Medical Association of Brandenburg [reference AS
30(a)/2011], Kantonale Ethikkommission Zuerich [refer-
ence 2013–0195], Hospital Vall d’ Hebron Clinical Re-
search Ethics Committee [reference TFS-ANT-2012-01]).
Screening and recruitment was performed at ten
sites, eight of which in the federal states of Berlin and
Brandenburg (Germany); one in Barcelona (Spain), and
one in Zurich (Switzerland). Patients admitted to the
respective emergency ward or stroke unit were
screened for trial eligibility based on selection criteria
listed in Table 1. If selection criteria were satisfied, and
patients or their legal representative agreed to partici-
pation, patients were randomized to either standard
medical care or additional daily PCTus measurements
with a recommendation to treat with antibiotics in case
PCTus > 0.05 ng/ml. An array of demographic parame-
ters, clinical and paraclinical stroke characteristics and
outcome information was collected. Patients were
followed up for a total of 6 months with assessment of
the primary endpoint (modified Rankin Scale, mRS)
analysed at 3 months after stroke. For more protocol
details please refer to the published trial protocol [21].
Data monitoring and analysis
All collected data for the Case Report Forms were moni-
tored. The mode of informed consent (personal by pa-
tient or by a legal representative) was assessed during
monitoring in a pseudonymized fashion. We calculated
descriptive statistics of patients’ demographics, their
basic stroke characteristics and outcome measures. We
furthermore compared the subgroups of the cohort
based on their ability to consent with Fisher’s exact test,
Chi-square, Mann-Whitney-U or with an independent
samples t-test, and correlated ordinal variables with abil-
ity to consent using Somers’ Δ. For multivariate testing,
we conducted logistic regression analysis using the step-
wise backward method for variable selection to avoid
omitted variable error. Statistics were calculated using
SPSS (Version 23, IBM, Armonk, NY).
Table 1 Major selection criteria of the STRAWINSKI trial
Domain Criterion
Age ≥ 18
Event to inclusion delay ≤ 40 h
Index Event Non-lacunar MCA infarct with an NIHSS
score > 9
Further criteria - no CT evidence of intracerebral
haemorrhage or lacunar infarct
- informed consent strictly personal or by
legal representative
- no use of antibiotics within last 10 days
- pre-stroke mRS of <4, life expectancy
> 3 months
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Results
We analysed 229 patients in the STRAWINSKI
intention-to-treat-cohort (Fig. 1) [20], for all of which
but one subject, information about the mode of consent
(120 in person vs. 108 by legal representative) was
available. Mean age of the cohort was 76.2 years ±11.3
Standard Deviation [SD], 55.5% of the participants were
female. Prior to stroke most patients (75.3%) lived at
home, which is reflected by a median pre-stroke mRS
of 0 (Interquartile Range [IQR] 0–2). At the time of ad-
mission, patients had a median NIHSS score of 14 (IQR
12–18). A relevant proportion of 21.8% presented with
a reduced state of vigilance. An infarct could be dem-
onstrated via imaging in 96.3% during their hospitalisa-
tion. Half of the patients underwent intravenous
thrombolysis (50.7%). Cardiac embolism was the most
abundant cause (50.2%) for stroke in our cohort
(Table 2).
When looking at those measures grouped by ability to
consent, the following differences appeared: Patients able
to consent were younger (p = 0.001), had a better pre-
stroke functional reserve as measured by mRS and were
more likely to live at home (p = 0.001 and Somers’ Δ =
0.304, p < 0.001, respectively). They were less severely af-
fected by stroke at admission (p < 0.001) measured by
NIHSS scores (Fig. 2). Patients able to consent were
less likely to suffer from reduced vigilance (Somers’
Δ = 0.340, p < 0.001). Furthermore, they had a less
predominant cardioembolic etiology profile than
their counterparts (p = 0.044). Patients with a middle
cerebral artery (MCA) infarction of the left hemi-
sphere were less likely to be able to consent (p <
0.001, Odds Ratio [OR] 4.5 95% Confidence Interval
[CI] 2.6–8.0), whereas MCA affection of the right
hemisphere was a strong positive predictor of ability
to consent (p < 0.001, OR 0.2 95% CI 0.1–0.4). It is
worth to note, that patients were evenly randomized
in terms of ability to consent in the exemplary trial
(p = 0.374, OR 0.9 95% CI 0.5–1.5).
The subjects in our cohort did persist to have a
median mRS of 5 (4–5) at their time of discharge,
also reflected by a low median Barthel Index (BI) of
10 (IQR 0–35). A majority of patients (72.9%) were
transferred to rehabilitation centers after stroke unit
care, only 7.1% were discharged home. During hospi-
talisation, 28.5% of patients suffered from pneumonia,
11% of urinary tract infections, 1.3% of sepsis, and
24.1% of other infections like respiratory tract infec-
tions not fulfilling criteria for pneumonia. A total of
43.6% of patients suffered from any infection. Fever
was recorded in 67.3%, 33.6% showed leucocytosis
and 8.5% of the patients suffered from delirium. A
proportion of 10.8% required mechanical ventilation
during their hospitalisation.
In terms of outcome measures, patients able to con-
sent had a significantly better outcome at discharge
measured by mRS and BI (p < 0.001 each). Patients un-
able to consent were more likely to die (p 0.004, OR
12.1 95% CI 1.5–96.5) and to develop fever (p 0.005, OR
2.3 95% CI 1.3–4.1). There was a trend to a higher rate
of infections in patients unable to consent (p = 0.061,
OR 1.7 95% CI 1.0–2.9). Further details on outcome pa-
rameters in the total cohort as well as grouped by ability
to consent are given in Table 3.
We then conducted a multivariate logistic regres-
sion analysis in which we included every variable that
showed a p-value ≤ 0.1 in univariate analysis. Using
the stepwise backward method we found several vari-
ables independently associated to ability to consent.
These variables express severity of stroke (NIHSS
score, p = 0.001; BI p = 0.059), pre-stroke functioning
(living independently at home, receiving assistance at
home or living in a nursing home; p = 0.01), location
of infarction (right MCA territory, p < 0.001) and
complications (dysphagia and fever during hospitalisa-
tion; p = 0.018 and p = 0.005, respectively) (see Table 4
for further details).
Fig. 1 Study Flow Chart. Two patients in the Intention-To-Treat-
Population violated selection criteria and were not included in the
main analysis of STRAWINSKI [20]
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Discussion
In order to improve future stroke care, clinical trials will
remain at the core of scientific progress. A key issue for
succeeding in these is the selection of a patient popula-
tion representative for “real world” stroke care. However,
including patients unable to give informed consent per-
sonally is an ethically challenging issue, faced with differ-
ent regulations in different countries or even between
federal states [5, 6]. Some countries developed a frame-
work by which acute treatment can be applied in emer-
gency conditions by waiver of consent [7, 8]. Here, we
explored whether exclusion of patients unable to con-
sent would lead to a selection bias in basic demograph-
ics and classic stroke characteristics as well as in typical
outcome parameters.
Our main findings are: 1) Patients able to consent
were younger and had less severe strokes in term of clin-
ical syndrome and functional deficit compared to pa-
tients unable to consent in an informed manner. 2)
Location of infarction was strongly associated with the
incapability to consent, most probably reflecting aphasia
and unconsciousness. 3) Patients being able to consent
had a higher level of pre-stroke functional independence
and were more likely to live at home at the time of
event. 4) Patients not being able to consent more fre-
quently developed fever and infections and were more
likely to have unfavourable outcome or even die in the
course of the disorder.
These findings corroborate previous reports demon-
strating stroke severity and localisation of infarction
Table 2 Basic demographics and stroke characteristics for the total cohort as well as patients able (strictly personal) and unable to
consent (legal representative)
Total cohort Strictly personal Legal representative P-value OR (95% CI)
n (%) 229 (100) 120 (52.6) 108 (47.4)
Age, mean (SD) 76.2 (11.3) 73.9 (11.0) 78.9 (11.3) 0.001 t-test
Sex, % female 55.5 50.0 61.1 0.110 1.6 (0.9–2.7)
Pre-stroke mRS, median (IQR) 0 (0–2) 0 (0–1) 1 (0–3) 0.001 MWU
Pre-stroke living, n (%) Somers‘Δ 0.304
Independent at home 171 (75.3) 102 (86.4) 68 (63.0)
Requiring help, but at home 34 (15.0) 12 (10.2) 22 (20.4)
Nursing or retirement home 22 (9.7) 4 (3.4) 18 (16.7)
Admission NIHSS, median (IQR) 14 (12–18) 13 (11–15) 17 (14–21) < 0.001 MWU
Consciousness, n (%) Somers’Δ 0.340
Awake 179 (78.2) 107 (89.2) 71 (65.7)
Somnolent 46 (20.1) 13 (10.8) 33 (30.6)
Comatose 4 (1.7) 0 (0.0) 4 (3.7)
Thrombolysis, n (%) 116 (50.7) 65 (54.2) 51 (47.2) 0.353 0.8 (0.5–1.3)
TOAST, n (%) 0.044 χ2
LAD 58 (26) 33 (28.2) 24 (22.9)
CAR 112 (50.2) 51 (43.5) 61 (58.1)
SVD 6 (2.7) 6 (5.1) 0 (0.0)
OTH 4 (1.8) 3 (2.6) 1 (1.0)
UNK 43 (19.3) 24 (20.5) 19 (18.1)
Dysphagia, n (%) 164 (77) 95 (81.9) 69 (71.9) 0.100 0.6 (0.3–1.1)
Imaging proof of infarction, n (%) 181 (96.3) 91 (97.8) 89 (94.7) 0.444 0.4 (0.1–2.1)
MCA infarction left 97 (42.9) 31 (26.3) 66 (61.7) < 0.001 4.5 (2.6–8.0)
MCA infarction right 121 (53.5) 83 (70.3) 37 (34.6) < 0.001 0.2 (0.1–0.4)
Brainstem lesion 7 (3.1) 7 (5.9) 0 (0.0) 0.015 0.9 (0.9–1.0)
Other location 15 (6.6) 7 (5.9) 8 (7.4) 0.791 1.3 (0.4–3.6)
Randomized to PCT-guidance 112 (49.3) 57 (47.9) 55 (50.9) 0.374 0.9 (0.5–1.5)
All p-values given are calculated using Fisher’s exact test except where explicitly stated a Somers’ Δ correlation, Mann-Whitney-U (MWU) or an independent samples
t-test; Abbreviations: mRS modified Rankin Scale, NIHSS National Institute of Health Stroke Scale score, MCA middle cerebral artery, TOAST Trial of ORG 10172
in Acute Stroke Treatment criteria, LAD Large Artery Disease, CAR cardiac embolism, SVD small vessel disease, OTH other cause, UNK unknown etiology
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being strongly associated with ability to consent. Patients
unable to consent are known to have higher admission
NIHSS and mRS scores [15]. Similar to the presented
study, the IST-3 investigators analysed the first 300 in-
cluded patients and their consenting documents, and
found stroke severity, type of clinical syndrome (motor
deficit, dysphasia and/or visuospatial disorder) and in-
farct localization to show significant differences depend-
ing on ability to consent [13]. In a further analysis the
consenting procedure was analysed in an academic
stroke centre across several acute stroke studies the
centre participated in. Again, greater age and greater
stroke severity as measured by Scandinavian Stroke
Scale were associated with inability to consent [3].
There are some limitations to this study: firstly, the re-
sults need to be interpreted with caution since we have
performed this analysis in a post-hoc manner and the
ability to consent was evaluated retrospectively from
consenting sheets. Thus, we cannot rule out that pa-
tients gave their consent orally and next-of-kins signed
as witnesses. Secondly, while we could analyse a robust
sample size, larger cohorts are needed to explore further
a
b
Fig. 2 Distribution of NIHSS scores (a) and localization of infarction (b) depending on ability to consent
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associations for different endpoints in other fields of
stroke research with a higher statistical power. How-
ever, the strengths of our study are the complete
data monitoring and the interventional trial setting.
To our knowledge this is the second clinical trial in
stroke research presenting differences within its co-
hort based on ability to consent, and the first to
present it from its total cohort instead of an interim
report.
Conclusions
Stroke patients’ ability to consent in an informed man-
ner to participate in a clinical study depends on several
demographic factors and stroke characteristics. Location
of infarction, severity of stroke and functional outcome
scales differ significantly between patients able or unable
to give consent. Clinical researchers investigating acute
stroke in general and post-stroke immunity and infec-
tions in particular as well as ethics review boards decid-
ing on trial protocols need to consider that patients with
inability to consent are more frequently aphasic, more
severely affected, older, and more likely to develop fever
and infections. We recommend bearing those differences
in mind when planning selection criteria for future clin-
ical trials. If (primary) outcome measures of a trial are
affected by this selection bias, it appears unethical to ex-
clude patients unable to consent. An international polit-
ical and legal framework i.e. embedded within the
International Conference on Harmonisation would be
immensely helpful to address this issue.
Additional file
Additional file 1: Full dataset supporting the manuscript. (CSV 60 kb)
Table 3 Outcome measures for the total cohort as well as patients able (strictly personal) and unable to consent (legal
representative)
Total cohort Strictly personal Legal representative P-value OR (95% CI)
Discharge mRS, median (IQR) 5 (4–5) 4 (4–5) 5 (4–5) < 0.001 MWU
Discharge BI, median (IQR) 10 (0–35) 25 (10–40) 5 (0–20) < 0.001 MWU
Discharge location, n (%) Somers‘Δ 0.094
Home 16 (7.8) 8 (7.3) 8 (8.5)
Rehabilitation hospital 164 (80.4) 92 (84.4) 71 (75.5)
Other acute care hospital 17 (8.3) 8 (7.3) 9 (9.6)
Nursing home 7 (3.4) 1 (0.9) 6 (6.4)
Death in hospital, n (%) 11 (4.8) 1 (0.8) 10 (9.3) 0.004 12.1 (1.5–96.5)
mRS at 3 months, median (IQR) 4 (3–6) 4 (3–5) 5 (4–6) < 0.001 MWU
Any SAE, n (%) 68 (29.7) 33 (27.5) 35 (32.4) 0.469 1.3 (0.7–2.2)
During hospitalisation, n (%)
Fever 152 (67.3) 69 (59.0) 83 (76.9) 0.005 2.3 (1.3–4.1)
Delirium 19 (8.5) 8 (6.8) 11 (10.4) 0.472 1.6 (0.6–4.1)
Leukocytosis 71 (33.6) 36 (32.1) 34 (34.7) 0.770 1.1 (0.6–2.0)
Mechanical ventilation 24 (10.8) 11 (9.4) 13 (12.4) 0.521 1.4 (0.6–3.2)
Infection, n (%) 99 (43.6) 44 (37.3) 54 (50.0) 0.061 1.7 (1.0–2.9)
Pneumonia 65 (28.5) 32 (26.9) 33 (30.6) 0.560 1.2 (0.7–2.1)
Sepsis 3 (1.3) 2 (1.7) 1 (0.9) 1.0 0.5 (0.1–6.1)
Urinary tract infection 25 (11.0) 12 (10.1) 13 (12.0) 0.676 1.2 (0.5–2.8)
Other infection 55 (24.1) 26 (21.8) 28 (25.9) 0.533 1.3 (0.7–2.3)
All p-values given are calculated using Fisher’s exact test except where explicitly stated a Mann-Whitney-U-test (MWU) or Somers’ Δ correlation; Abbreviations:
mRS modified Rankin Scale, BI Barthel Index, SAE serious adverse event, PCT procalcitonin
Table 4 Associations of demographic and stroke characteristics
in patients able (strictly personal) and unable to consent (legal
representative) in a multivariate logistic regression model
P-value OR (95% CI)
Pre-stroke living 0.010 2.33 (1.23–4.43)
Admission NIHSS score 0.001 1.22 (1.08–1.38)
Dysphagia 0.018 0.30 (0.11–0.82)
MCA Infarction right <0.001 0.15 (0.06–0.37)
Discharge BI 0.059 0.98 (0.96–1.00)
Fever during hospitalisation 0.005 3.87 (1.51–9.90)
All values obtained by logistic regression with stepwise backwards exclusion.
All predictors showing association of p ≤ 0.1 in univariate analysis were
included in the analysis; Abbreviations: NIHSS National Institute of Health
Stroke Scale, MCA middle cerebral artery, BI Barthel Index
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Abbreviations
BI: Barthel-Index; CAR: Cardioembolism as defined by TOAST; CI: Confidence
Interval; IQR: Interquartile Range; IST-3: Third international stroke trial;
LAD: Large artery disease as defined by TOAST; MCA: Middle cerebral artery;
mRS: modified Rankin Scale; MWU: Mann-Whitney U test; NIHSS: National
Institute of Health Stroke Scale; OR: Odds Ratio; OTH: Other as defined by
TOAST; PCTus: Ultrasensitive Procalcitonin; SAE: Serious Adverse Event;
SAP: SAP; SD: Standard Deviation; STRAWINSKI: Stroke Adverse Outcome Is
Associated with Nosocomial Infections Trial; SVD: Small vessel disease as
defined by TOAST; TOAST: Trial of ORG 10172 in Acute Stroke Treatment;
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